A Playbook for FDA Inspections and Remediation with Jeff Hines
Episode
52 min
Read time
2 min
Topics
Productivity, Leadership, Software Development
AI-Generated Summary
Key Takeaways
- ✓Inspection Room Infrastructure: Structure inspections across four dedicated rooms: a front room with quality and technical leads, a backroom staffed with IT-fluent document retrievers connected via Teams or Zoom chat for parallel request processing, a document review room with department SMEs, and a preparation room where experienced staff role-play inspector conversations with employees before they enter.
- ✓Leadership Demeanor as Risk Control: A leader's visible calm directly regulates team anxiety during inspections. Operators and analysts know their jobs better than anyone, so leaders should frame inspections as an opportunity to demonstrate competence, not a threat. Equally, coach employees to answer only what is asked — volunteering excess information creates unintended threads for inspectors to pull.
- ✓Remediation Prioritization Framework: When managing a large observation backlog alongside ongoing manufacturing, sequence work by regulatory urgency: stability samples first, prefill or in-process tests second, and discretionary studies last. Communicate trade-offs explicitly to internal customers. Use color-coded project tracking to build team momentum by closing easier observations before tackling complex, multi-department findings.
- ✓Data Integrity Gap Mapping: When addressing data integrity observations, create step-by-step data flow maps tracing every action from test initiation to final result, identifying each point where an analyst interfaces with the IT system. This process, applied at both laboratory and manufacturing levels, surfaces unknown vulnerabilities — such as audit trail manipulation capabilities — that standard SOP validation procedures routinely miss.
- ✓Compliance Culture Maintenance: Prevent repeat findings by institutionalizing annual GMP update training that reviews observations from both internal sites and external companies, tracks regulatory shifts, and updates procedures accordingly. Treat quality as a value center rather than a cost center. Invest in conference attendance and regulatory publications, and build bench depth so inspection readiness does not depend on a single experienced individual.
What It Covers
Jeff Hines, VP of Quality at Karuna Medical with 37 years of pharmaceutical industry experience including 30 years at Eli Lilly, outlines leadership strategies for navigating FDA inspections across PAI, routine, and for-cause scenarios, covering inspection infrastructure, remediation execution, employee morale, and building lasting compliance culture.
Key Questions Answered
- •Inspection Room Infrastructure: Structure inspections across four dedicated rooms: a front room with quality and technical leads, a backroom staffed with IT-fluent document retrievers connected via Teams or Zoom chat for parallel request processing, a document review room with department SMEs, and a preparation room where experienced staff role-play inspector conversations with employees before they enter.
- •Leadership Demeanor as Risk Control: A leader's visible calm directly regulates team anxiety during inspections. Operators and analysts know their jobs better than anyone, so leaders should frame inspections as an opportunity to demonstrate competence, not a threat. Equally, coach employees to answer only what is asked — volunteering excess information creates unintended threads for inspectors to pull.
- •Remediation Prioritization Framework: When managing a large observation backlog alongside ongoing manufacturing, sequence work by regulatory urgency: stability samples first, prefill or in-process tests second, and discretionary studies last. Communicate trade-offs explicitly to internal customers. Use color-coded project tracking to build team momentum by closing easier observations before tackling complex, multi-department findings.
- •Data Integrity Gap Mapping: When addressing data integrity observations, create step-by-step data flow maps tracing every action from test initiation to final result, identifying each point where an analyst interfaces with the IT system. This process, applied at both laboratory and manufacturing levels, surfaces unknown vulnerabilities — such as audit trail manipulation capabilities — that standard SOP validation procedures routinely miss.
- •Compliance Culture Maintenance: Prevent repeat findings by institutionalizing annual GMP update training that reviews observations from both internal sites and external companies, tracks regulatory shifts, and updates procedures accordingly. Treat quality as a value center rather than a cost center. Invest in conference attendance and regulatory publications, and build bench depth so inspection readiness does not depend on a single experienced individual.
Notable Moment
Hines describes accepting an FDA observation he strongly disagreed with — a lab had tightened statistical controls to three injections at 1.1% RSD instead of six at 2%, demonstrating equal or higher confidence. He reverted to the standard method anyway, concluding some battles cost more than the compliance inconvenience they solve.
You just read a 3-minute summary of a 49-minute episode.
Get The Life Science Rundown summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Life Science Rundown
TerSera's VP of Quality on the Audit Risk Hiding Inside Your Own Procedures
May 18 · 30 min
Eye on AI
#341 Celia Merzbacher: Beyond the Buzzword: The Real State of Quantum Computing, Sensing, and AI in 2025
Apr 30
More from The Life Science Rundown
What Auditors Are Actually Looking For — and the Psychology Behind How They Find It
Apr 28 · 19 min
The Joe Rogan Experience
#2451 - Cheryl Hines
Feb 10
More from The Life Science Rundown
We summarize every new episode. Want them in your inbox?
TerSera's VP of Quality on the Audit Risk Hiding Inside Your Own Procedures
What Auditors Are Actually Looking For — and the Psychology Behind How They Find It
Why Kidney Disease Innovation Is a Tale of Two Cities — and What It Would Take to Change That
Syncing Global Regulatory Filings Across FDA, EMA, and PMDA with AJ Acker
Navigating Regulatory Leadership Across Large and Small Life Science with Tammy Sarnelli
Similar Episodes
Related episodes from other podcasts
Eye on AI
Apr 30
#341 Celia Merzbacher: Beyond the Buzzword: The Real State of Quantum Computing, Sensing, and AI in 2025
The Joe Rogan Experience
Feb 10
#2451 - Cheryl Hines
Drug Story
Feb 10
Testosterone and "Low T"
The Vergecast
Jan 23
The end of the Sony era in TVs
The Changelog
Jan 19
Agent psychosis: are we going insane? (News)
Explore Related Topics
This podcast is featured in Best Science Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Software Engineering Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Life Science Rundown.
Every Monday, we deliver AI summaries of the latest episodes from The Life Science Rundown and 192+ other podcasts. Free for up to 3 shows.
Start My Monday DigestNo credit card · Unsubscribe anytime